Rigel Pharma Shares Fall After FDA Guidance on Anemia Treatment

 Shares of Rigel Pharmaceuticals Inc. were lower in Monday's late-trading session, after the company said it received "guidance from the U.S. Food and Drug Administration's review of the company's re-analysis of data from the FORWARD Phase 3 trial of fostamatinib for the treatment of patients with warm autoimmune hemolytic anemia."

Based on the guidance, the company said it doesn't expect to file a supplemental new drug application for the indication at this time.

The company also said it was cutting its workforce by 16%. The move will see 30 positions be eliminated, primarily in development and administration, Rigel said.

At 4:53 p.m. ET, the company's shares were trading 16.75% lower at $94 cents a share. The stock finished the day's regular session flat at $1.14 a share.

"Rigel will continue to explore its options for the wAIHA program in relation to its complete portfolio of development opportunities," the company said.

https://www.marketscreener.com/quote/stock/RIGEL-PHARMACEUTICALS-IN-10674/news/Rigel-Pharma-Shares-Fall-16-After-FDA-Guidance-on-wAIHA-Treatment-41974748/